CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer Gao, Tatiana M. Prowell, Julia A. Beaver et al.|The Lancet Oncology|2019Cited by 299
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Richard Pazdur, Amanda J. Walker et al.|Clinical Cancer Research|2018Cited by 98
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Richard Pazdur, Julia A. Beaver et al.|Clinical Cancer Research|2016Cited by 80
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Richard Pazdur, Michael H. Brave et al.|Clinical Cancer Research|2016Cited by 54
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael H. Brave, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 29